New Study Confirms RUTISS Responsiveness in Recurrent UTI Assessment
Peer-reviewed evidence establishes a 6.5point MCID, reinforcing the RUTISS as the first fully validated Patient Reported Outcome Measure for recurrent urinary tract infection.
New peer reviewed evidence has confirmed the responsiveness of the Recurrent UTI Symptom Scale (RUTISS), reinforcing its position as the first fully validated Patient Reported Outcome Measure (PROM) designed specifically for recurrent urinary tract infection.
The study, published in Urology, assessed changes in patient reported symptoms during antibiotic treatment and demonstrated that the RUTISS is highly sensitive to clinically meaningful improvement. The research also established a Minimal Clinically Important Difference (MCID) of 6.5 points, providing a robust threshold for interpreting symptom change in both clinical research and practice.
Analysis showed:
- Excellent responsiveness, with strong discrimination between improved and nonimproved patients
- Consistent performance across subscales, particularly urinary symptoms, urinary presentation, and UTI pain and discomfort
- Strong correlations with established patient reported anchors, supporting convergent validity and confirming the measure’s sensitivity to change
As the only PROM developed specifically for the assessment of symptom burden in recurrent UTI, the RUTISS addresses a longstanding gap. Its validated responsiveness and MCID support its use as a clinical trial endpoint, within real world treatment evaluation, and in routine clinical monitoring, providing researchers and clinicians with a patient centred and psychometrically rigorous tool.
InSpired Health Outcomes manages the RUTISS on behalf of its developers, PARED Insights, facilitating its use across clinical research and healthcare settings. Organisations implementing the measure can access licensing, digital permissions, translation support, and methodological expertise to ensure appropriate application.
This new evidence further strengthens the RUTISS as a robust and clinically interpretable measure capable of advancing recurrent UTI research and enhancing understanding of treatment impact.
Putting patients at the heart of healthcare — where they belong.